Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618967 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of AMG 570 in Healthy Subjects
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02618967 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 56 participants.
The verdict
NCT02618967, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad), pharmacokinetics (what the body does to the drug), and pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.
Interventions
- BIOLOGICAL AMG 570
- BIOLOGICAL AMG 570 Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2016-03-28 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02618967
The ClinicalTrials.gov registry entry for NCT02618967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG 570 is the first listed.
NCT02618967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02618967 about?
NCT02618967 is a clinical study titled "Single Ascending Dose Study of AMG 570 in Healthy Subjects". The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad), pharmacokinetics (what the body does to the drug), and pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.
What is the current status of trial NCT02618967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2016-03-28. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT02618967?
The interventions under investigation include: AMG 570 (BIOLOGICAL), AMG 570 Matching Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02618967?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.